Hot Products
| Catalog No. | Information |
| CFN91180 | Bancroftinone Reference standards. |
| CFN00155 | Baogongteng A Baogongteng A and Baogongteng C are the major toxic chemical compounds of the Erycibe species. Baogongteng A analogs as effective muscarinic agonists or antagonists in clinical use.Baogongteng A is a new tropane alkaloid used for treating glaucoma, synthetic baogongteng A also shows myotic activities in rabbits, but the potency is half of that of the natural product. |
| CFN00154 | Baogongteng C Baogongteng A and Baogongteng C are the major toxic chemical compounds of the Erycibe species. |
| CFN98525 | Baohuoside I Baohuoside I is a novel immunosuppressive molecule, exhibits antimetastatic, anti-osteoporosis, anti-inflammatory and anti-cancer activities. Baohuoside I can inhibit the proliferation of Eca-109 cells, this effect associats with down-regulation expression of β-catenin,Cyclin D1,Survivin,and their proteins,which affects on the Wnt/β-catenin signaling pathway. |
| CFN90764 | Baohuoside II Baohuoside aglycone possesses cardioprotective effect in prevention of ischemia/ reperfusion injury and reduce the myocardial infraction, the mechnism is due to the reduction of the injury of free radicals. |
| CFN90763 | Baohuoside V Reference standards. |
| CFN90765 | Baohuoside VII Baohuoside aglycone possesses cardioprotective effect in prevention of ischemia/ reperfusion injury and reduce the myocardial infraction, the mechnism is due to the reduction of the injury of free radicals. Baohuoside VII in vivo exhibits significant anti-osteoporosis activity. |
| CFN91986 | Baptifoline Baptifoline has cytotoxic activity. |
| CFN96162 | Barbinervic acid Barbinervic acid shows anti-bacteria activity (IC50 = 0.098 g x LU(-1), IC50 = 0.27 g x L(-1)) against SA and ESBLs-SA respectively. |
| CFN92689 | Batatasin III Batatasin III may have a long-term inhibitory effect on whole plant growth, shows germination inhibitory activity. Batatasin III may impose a lethal effect on the aquatic fauna in small streams. |
